Suono Bio, Inc. Announces Oversubscribed Series A Funding Round Led by Axil Capital and Mizuho Securities Principal Investment

13 Jul, 2021

Suono Bio, Inc. Announces Oversubscribed Series A Funding Round Led by Axil Capital and Mizuho Securities Principal Investment
Photo by Simone Pellegrini on Unsplash

– Suono Bio, Inc. has raised an $8.5m Series A financing led by Axil Capital and Mizuho Securities Principal Investment, with participation by Taiwania Capital and other investors.
– Suono Bio will utilize the funds to advance its lead programs in inflammatory bowel disease as well as expansion of its pipeline.
– The company leverages technology developed in the laboratory of Institute Professor Robert Langer at the Massachusetts Institute of Technology (MIT) to facilitate rapid, local administration of therapeutics to treat serious diseases.
– The company was founded by Professor Langer, Professor Giovanni Traverso, from the Department of Mechanical Engineering at MIT and a gastroenterologist and biomedical engineer at Brigham and Women’s Hospital, Harvard Medical School, and Dr. Carl Schoellhammer.

Biotechnology Health Care Medical Medical Device North America
Crunchbase icon

Content report

The following text will be sent to our editors: